The Faculty of Medicine at the University of Helsinki conducts high-quality research and provides research-based basic and post-graduate education in medicine and dentistry, psychology and logopedics. The Faculty of Medicine at the University of Helsinki is located in the Meilahti-Ruskeasuo Campus, offering excellent opportunities for close collaboration with both the University Hospital and public sector research institutes (the National Institute of Health and Welfare, the Finnish Institute of Occupational Health). In addition to teaching and research, the Faculty serves as an important authority in the field of health care and actively participates in ethical discourse. The Faculty aims to become one of the most highly reputed medical faculties in the world as well as to maintain and to strengthen its position as a Centre of Excellence in teaching.

The Faculty of Medicine of the University of Helsinki, together with Helsinki University Central Hospital (HUCH) and the Institute for Molecular Medicine Finland (FIMM) form the Academic Medical Center Helsinki (AMCH). This medical unit is ranked among the 10 best medical centers at European level and the 50 best centers in the world

Faculty of Medicine, Barboric laboratory, invites applications for a position of
Postdoctoral Fellow or Graduate Student
in the field of RNA Polymerase II Gene Transcription for a fixed-term

The Barboric Lab is committed to elucidating fundamental mechanisms, which control the elongation phase of transcription by RNA polymerase II (Pol II) in normal and disease states. We are interested in essential cyclin-dependent kinases, which trigger Pol II release from promoter-proximal pausing and facilitate productive Pol II elongation along genes. We employ biochemistry, genetics and genome wide approaches to understand how Pol II pause release is, controlled by the positive transcription elongation factor (P-TEFb) and its inhibitory 7SK snRNP complex. Moreover, we are examining how another critical Pol II elongation kinase, Cdk12/CycK, impacts target gene expression, and how frequent CDK12 cancer mutations perturb gene expression to enable tumorigenesis. Finally, we are aiming to define novel mechanisms that promote integration of Pol II transcription with maturation of precursor RNA transcripts.

The University of Helsinki is a research oriented university which offers stimulating and international environment. Faculty of Medicine offers a unique and stimulating research environment surrounded by state-of-the-art resources and facilities of the leading and largest biomedical research campus in Finland. http://www.bio-med.helsinki.fi/english/
Employees of the University of Helsinki are covered by excellent occupational health care.

We are looking for a creative thinker with strong analytical skills and a passion for science. We expect you to formulate your own hypotheses, propose experimental design to address them, and take advantage of the laboratory/research community’s intellectual and skill resources to advance the knowledge of the field. The competitive candidate should hold MSc or PhD degree in molecular biology, biochemistry, biotechnology or related fields. Wide expertise in biochemistry and molecular biology is a pre-requisite for the position. In addition, we appreciate expertise in the analysis of NGS data.

Excellent publication record as well as good command in spoken and written English is required.

Salary is based on the Universities salary scheme for teaching and research personnel composed of both task specific and personal performance components. A trial period of four months will be applied.

Your application should include a cover letter, CV, summary of your interests, and two or three letters of reference.

Please submit your application, together with the required attachment, through the University of Helsinki electronic recruitment system by clicking on Apply for job. Internal applicants (i.e., current employees of the University of Helsinki) must submit their applications through the SAP HR portal.

The closing date for applications is December 4, 2017.

For further information, please contact Ph.D Matjaz Barboric, matjaz.barboric(at)helsinki.fi
http://www.biomed.helsinki.fi/research/barboriclab/index.html

Recent publications:
Ekumi KM, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 2015; 43:2575-2589. Barboric M, Fujinaga K. The two sides of Tat, Elife 2016; doi: 10.7554/eLife.12686.
Quaresma AJ, Bugai A, Barboric M. Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb, Nucleic Acids Res. 2016; 44:7527-7539.
Bugai A, et al. RBM7 activates P-TEFb for a pro-survival transcriptional response to DNA damage. 2017; Submitted.

Hae viimeistään 04.12.2017

Haku päättyy

maanantai, joulukuu 4, 2017